Mental state: clinically important change in general mental state ‐ worsening psychosis · schizophrenia or related disorders
Modafinil showed no clear difference in mental state: clinically important change in general mental state ‐… compared with placebo (low certainty).
1 finding from 1 review
Cognitive function: average endpoint score** · schizophrenia or related disorders
1 finding from 1 review
Adverse effect/event(s) ‐ serious adverse events · schizophrenia or related disorders
It is very uncertain whether modafinil changes adverse effect/event(s) ‐ serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Global state: clinically important change in global state · schizophrenia or related disorders
It is very uncertain whether modafinil changes global state: clinically important change in global state compared with placebo (very low certainty).
1 finding from 1 review
Leaving the study early · schizophrenia or related disorders
Modafinil showed no clear difference in leaving the study early ‐ for any reason compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life: 1a. Average endpoint scores on various scales (MSQoL‐54, high = good) ‐ short term · schizophrenia or related disorders
1 finding from 1 review
Hospital admissions · schizophrenia or related disorders
It is very uncertain whether modafinil changes service use: hospital admission compared with placebo (very low certainty).
1 finding from 1 review
Epworth Sleepiness Scale (ESS), week 3№ of participants: 101(2 RCTs) · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
High
Number of naps/week, week 3№ of participants: 99(2 RCTs) · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Low
Clinical Global Impression ‐ Severity (CGI‐S), change from baseline№ of participants: 30(1 RCT) · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Clinical Global Impression ‐ Change (CGI‐C), proportion much improved or very much improved at week 3 № of participants: 70 (1 RCT) · idiopathic hypersomnia
Modafinil probably leads to higher clinical Global Impression ‐ Change (CGI‐C), proportion much… compared with placebo (moderate certainty).
1 finding from 1 review
OR 5.14 [1.76, 15]
Studies not reported
Moderate
improvement in the maintenance of wakefulness test · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
High
Effectiveness · idiopathic hypersomnia
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Number of participants with any adverse events№ of participants: 102(2 RCTs) · idiopathic hypersomnia
Modafinil showed no clear difference in number of participants with any adverse events№ of participants:… compared with placebo (low certainty).
1 finding from 1 review
OR 1.68 [0.28, 9.94]
Studies not reported
Low
Fatigue · people with ALS/MND
1 finding from 1 review
Adverse events · people with ALS/MND
1 finding from 1 review
Change in apathy · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review
Adverse Events ‐ reported, but not analyzed in this review · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in NPS ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in cognition ‐ not investigated · Apathy in people with mild‐to‐moderate Alzheimer's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found